A joint degree with the Graduate School of Arts and Sciences through the Harvard Department of Stem Cell and Regenerative Biology
The world needs more leaders working at the intersection of science and society, with deep understanding of biotechnology, life sciences, and management. To meet this need, the MS/MBA Biotechnology: Life Sciences Program at Harvard University builds upon students’ existing biotech and life sciences knowledge and equips them with the latest business and scientific insights. This empowers them to grow transformative organizations that will advance new drug discoveries or therapeutics.
The curriculum emphasizes an understanding of effective, sustainable business models for discovery and development, the ethical implications of new therapeutics, and equitable access to the fruits of therapeutic discovery.
Harvard offers a joint degree program that confers an MBA from Harvard Business School and a Master of Science from the Graduate School of Arts and Sciences in the Harvard Department of Stem Cell and Regenerative Biology, a Faculty of Arts and Sciences/Harvard Medical School joint department. The program is completed over two academic years, utilizing January terms and time in August at the start of the program.
Upon completion of the program, graduates will be able to:
- Assess the potential therapeutic value of discoveries emanating from lab-discovery in the life sciences and understand ways to accelerate these discoveries into therapeutics.
- Lead science-based organizations, including businesses and non-profits, with an understanding of research culture, relevant timeframes, opportunity-costs, rewards, and organizational behavior.
- Determine the most promising strategy for science-based organizations, including novel ways for expanding access to transformative therapies.
- Understand the financial underpinnings of investment decisions in the life sciences, including real-option approaches to investments, as well as the role of scientific, commercial, policy, and regulatory uncertainties in affecting these opportunities.
- Develop approaches to ethical dilemmas bedeviling novel therapeutics, including investment in neglected diseases, the provision of life-saving drugs to disadvantaged patients and those in the developing world, and the pricing of medicines.
Interested in learning more? Fill out an Introduce Yourself form to stay in touch.